Archived Facts

(Reuters) – Johnson & Johnson is close to reaching a settlement with the U.S. Justice Dept. over allegations it promoted its antipsychotic Risperdal for unapproved uses that could cost the healthcare conglomerate at least $ 1.5 billion, the Wall Street Journal reported on Wednesday.

Popular Posts:

Related Posts:

Leave a Reply